156 related articles for article (PubMed ID: 37958502)
21. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Li Y; Yang Z; Li W; Xu S; Wang T; Wang T; Niu M; Zhang S; Jia L; Li S
Oncotarget; 2016 Feb; 7(6):6748-64. PubMed ID: 26745678
[TBL] [Abstract][Full Text] [Related]
22. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells.
Abe Y; Matsumoto S; Kito K; Ueda N
J Biol Chem; 2000 Jul; 275(28):21525-31. PubMed ID: 10781613
[TBL] [Abstract][Full Text] [Related]
23. Targeting PRPK and TOPK for skin cancer prevention and therapy.
Roh E; Lee MH; Zykova TA; Zhu F; Nadas J; Kim HG; Bae KB; Li Y; Cho YY; Curiel-Lewandrowski C; Einspahr J; Dickinson SE; Bode AM; Dong Z
Oncogene; 2018 Oct; 37(42):5633-5647. PubMed ID: 29904102
[TBL] [Abstract][Full Text] [Related]
24. Xanthohumol inhibits non-small cell lung cancer via directly targeting T-lymphokine-activated killer cell-originated protein kinase.
Zhao S; Cui J; Cao L; Han K; Ma X; Chen H; Yin S; Zhao C; Ma C; Hu H
Phytother Res; 2023 Jul; 37(7):3057-3068. PubMed ID: 36882184
[TBL] [Abstract][Full Text] [Related]
25. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
26. ADA-07 Suppresses Solar Ultraviolet-Induced Skin Carcinogenesis by Directly Inhibiting TOPK.
Gao G; Zhang T; Wang Q; Reddy K; Chen H; Yao K; Wang K; Roh E; Zykova T; Ma W; Ryu J; Curiel-Lewandrowski C; Alberts D; Dickinson SE; Bode AM; Xing Y; Dong Z
Mol Cancer Ther; 2017 Sep; 16(9):1843-1854. PubMed ID: 28655782
[TBL] [Abstract][Full Text] [Related]
27. T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Thanindratarn P; Wei R; Dean DC; Singh A; Federman N; Nelson SD; Hornicek FJ; Duan Z
Mol Oncol; 2021 Dec; 15(12):3721-3737. PubMed ID: 34115928
[TBL] [Abstract][Full Text] [Related]
28. The Protective Role of the TOPK/PBK Pathway in Myocardial Ischemia/Reperfusion and H₂O₂-Induced Injury in H9C2 Cardiomyocytes.
Sun G; Ye N; Dai D; Chen Y; Li C; Sun Y
Int J Mol Sci; 2016 Feb; 17(3):267. PubMed ID: 26907268
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon.
Xiao J; Duan Q; Wang Z; Yan W; Sun H; Xue P; Fan X; Zeng X; Chen J; Shao C; Zhu F
Oncotarget; 2016 Apr; 7(17):24483-94. PubMed ID: 27016416
[TBL] [Abstract][Full Text] [Related]
30. Acetylshikonin suppresses diffuse large B-Cell Lymphoma cell growth by targeting the T-lymphokine-activated killer cell-originated protein kinase signalling pathway.
Cui J; Guo R; Wang Y; Song Y; Song X; Li H; Song X; Li J
Bioengineered; 2022 Feb; 13(2):4428-4440. PubMed ID: 35139768
[TBL] [Abstract][Full Text] [Related]
31. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
32. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
33. PDZ-binding kinase/T-LAK cell-originated protein kinase is a target of the fucoidan from brown alga Fucus evanescens in the prevention of EGF-induced neoplastic cell transformation and colon cancer growth.
Vishchuk OS; Sun H; Wang Z; Ermakova SP; Xiao J; Lu T; Xue P; Zvyagintseva TN; Xiong H; Shao C; Yan W; Duan Q; Zhu F
Oncotarget; 2016 Apr; 7(14):18763-73. PubMed ID: 26936995
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase.
Zheng M; Luan S; Gao S; Cheng L; Hao B; Li J; Chen Y; Hou X; Chen L; Li H
Oncotarget; 2017 Jun; 8(24):39143-39153. PubMed ID: 28388576
[TBL] [Abstract][Full Text] [Related]
35. Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC.
Xiao J; Zhang L; Yi H; Zou L; Mo J; Xue F; Zheng J; Huang Y; Lu H; Wu H; Xue P; Zhang X; He L; Li Z; Pang S; Qiao G; Duan Q; Zhu F
Cell Death Dis; 2022 Sep; 13(9):828. PubMed ID: 36167821
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours.
Deng M; Yang R; Sun Q; Zhang J; Miao J
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):629-642. PubMed ID: 38501576
[TBL] [Abstract][Full Text] [Related]
37. T-lymphokine-activated killer cell-originated protein kinase functions as a positive regulator of c-Jun-NH2-kinase 1 signaling and H-Ras-induced cell transformation.
Oh SM; Zhu F; Cho YY; Lee KW; Kang BS; Kim HG; Zykova T; Bode AM; Dong Z
Cancer Res; 2007 Jun; 67(11):5186-94. PubMed ID: 17545598
[TBL] [Abstract][Full Text] [Related]
38. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway.
Wu W; Xu J; Gao D; Xie Z; Chen W; Li W; Yuan Q; Duan L; Zhang Y; Yang X; Chen Y; Dong Z; Liu K; Jiang Y
Cell Death Dis; 2023 Jun; 14(6):364. PubMed ID: 37328464
[TBL] [Abstract][Full Text] [Related]
39. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
[TBL] [Abstract][Full Text] [Related]
40. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
